Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

@inproceedings{Gruber2018MonitoringOE,
  title={Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model},
  author={Andrea Gruber and Martin Czejka and Philipp Buchner and Marie Kitzmueller and Nairi Kirchbaumer Baroian and Christian Dittrich and Azra Sahmanovic Hrgovcic},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2018}
}
In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a physiologically based pharmacokinetic (PBPK) model was created to assess such variations in silico. Patients with advanced pancreatic cancer received a… CONTINUE READING